Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: pemetrexed
Drug: enzastaurin
Drug: placebo
Drug: cisplatin

First Posted Date: 2007-10-03

Last Posted Date: 2020-11-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT00538681

Locations: 🇷🇴
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Enzastaurin
Drug: Bevacizumab
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2

Registration Number: NCT00536939

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States

A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Duloxetine hydrochloride
Drug: Placebo

First Posted Date: 2007-09-27

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 776

Registration Number: NCT00536471

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: enzastaurin
Drug: carboplatin
Drug: pemetrexed
Drug: bevacizumab
Drug: Placebo

First Posted Date: 2007-09-21

Last Posted Date: 2021-05-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 40

Registration Number: NCT00533429

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States

Duloxetine - Warfarin Pharmacodynamic Study

Phase 1

Completed

Conditions: Anticoagulant Effect of Warfarin When Taken With Duloxetine.

Interventions: Drug: Duloxetine
Drug: Warfarin

First Posted Date: 2007-09-21

Last Posted Date: 2008-10-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT00533026

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Leeds, West Yorkshire, United Kingdom

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Metastatic Malignant Melanoma

Interventions: Biological: IMC-1121B (ramucirumab)
Drug: Dacarbazine

First Posted Date: 2007-09-21

Last Posted Date: 2014-08-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 106

Registration Number: NCT00533702

Locations: 🇺🇸
ImClone Investigational Site, Seattle, Washington, United States

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

Phase 4

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: raloxifene
Drug: Placebo

First Posted Date: 2007-09-20

Last Posted Date: 2007-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT00532246

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Walnut Creek, California, United States

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: teriparatide

First Posted Date: 2007-09-20

Last Posted Date: 2007-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT00532207

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation

Bone Marker Changes With Teriparatide/Postmenopausal Osteoporosis

Phase 4

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: Teriparatide

First Posted Date: 2007-09-20

Last Posted Date: 2007-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 45

Registration Number: NCT00532545

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Long Term Effects of Raloxifene Treatment on Bone Quality

Phase 4

Completed

Conditions: Osteoporosis, Post-Menopausal

Interventions: Drug: Raloxifene
Drug: Placebo

First Posted Date: 2007-09-20

Last Posted Date: 2007-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT00532428

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy